Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 3Irinotecan 2tivozanib 1surufatinib 1sintilimab 1repotrectinib 1pralsetinib 1copper dotatate CU-64 1atezolizumab 1Topotecan 1Specimen Handling 1Nivolumab 1Neoadjuvant Therapy 1Melphalan 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interferon-alpha 1Gemcitabine 1Fluorodeoxyglucose F18 1Everolimus 1Etoposide 1Copper 1Carboplatin 1Biopsy 1BAY 1895344 1Aromatherapy 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × BAY 1895344 × Gastrointestinal × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡